Drug Trial Radar · NCT02308111
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis
Last checked: Nov 20, 2026Latest source record: Mar 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
334
Actual
Start
Dec 26, 2014
Primary completion
Dec 23, 2021
Study completion Dec 23, 2021
Sponsor
- Lead sponsor
- Intercept PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Dec 4, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Biliary Cholangitis (PBC) is a serious, life-threatening, bile acid related liver disease of unknown cause. Without treatment, it frequently progresses to liver fibrosis and eventual cirrhosis requiring liver transplantation or resulting in death. The investigational drug, Obeticholic Acid (OCA) is a modified bile acid and FXR agonist that is derived from the primary human bile acid chenodeoxycholic acid. The key mechanisms of action of OCA, including its choleretic, anti-inflammatory, and anti-fibrotic properties, underlie its hepatoprotective effects and result in attenuation of injury and improved liver function in a cholestatic liver disease such as PBC. The study will assess the effect of OCA compared to placebo, combined with stable standard care, on clinical outcomes in PBC participants.
Conditions
- Liver Cirrhosis, Biliary
Interventions
Obeticholic Acid (OCA)Drug
Non-cirrhotic and classified as CP Class A: 5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily based on tolerability at 3 months for the duration of the study (majority of participants). Cirrhotic and classified as CP Class B and C: 5 mg tablet of OCA once weekly for at least 3 months, subsequently titrating up to a maximum dose and frequency of 10 mg OCA twice weekly based on tolerability and biochemical response for the duration of the study.
PlaceboDrug
One tablet daily (or a lower frequency depending on CP score) for the remainder of the study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to the First Occurrence of Composite EndpointTime frame: Time to first occurrence from date of randomization until the time to accrue approximately 127 primary endpoint events (up to 7 years)
- Time to the First Occurrence of Primary Clinical Event (Expanded Endpoint)Time frame: Time to first occurrence from date of randomization until the time to accrue approximately 127 primary endpoint events (up to 7 years)
Locations
181 sites in 31 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona
Cedars-Sinai Medical Center
Los Angeles, California
Inland Empire Liver Foundation
Rialto, California
University of California Davis, Davis Medical Center
Sacramento, California
Stanford University
Stanford, California
University of Colorado Denver and Hospital
Aurora, Colorado
UF Hepatology Research at CTRB
Gainesville, Florida
Schiff Center for Liver Diseases/University of Miami
Miami, Florida
Piedmont Atlanta Hospital
Atlanta, Georgia
Emory University Hospital
Atlanta, Georgia
Gastrointestinal Specialists of Georgia
Marietta, Georgia
Northwestern University Feinberg School of Medicine
Chicago, Illinois
University of Chicago Medical Center
Chicago, Illinois
Indiana University
Indianapolis, Indiana
Indianapolis Gastroenterology Research Foundation
Indianapolis, Indiana
University of Louisville, Medical Dental Complex
Louisville, Kentucky
Tulane University Medical Center
New Orleans, Louisiana
Mercy Medical Center
Baltimore, Maryland
UMass Medical School
Worcester, Massachusetts
Henry Ford Health System
Novi, Michigan
Minnesota Gastroenterology, P.A.
Saint Paul, Minnesota
Southern Therapy and Advanced Research (STAR)
Jackson, Mississippi
Kansas City Research Institute
Kansas City, Missouri
Saint Louis University Gastroenterology & Hepatology
St Louis, Missouri
Saint Joseph's Regional Medical Center
Paterson, New Jersey
Mount Sinai Beth Israel
New York, New York
Weill Cornell Medical College
New York, New York
University of Rochester Medical Center
Rochester, New York
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Quality Medical Research, PLLC
Nashville, Tennessee
The Liver Institute at Methodist Dallas Medical Center
Dallas, Texas
Baylor University Medical Center
Dallas, Texas
Texas Digestive Disease Consultants
Dallas, Texas
UT Southwestern Medical Center
Dallas, Texas
Brooke Army Medical Center
Fort Sam Houston, Texas
Baylor Scott and White Research Institute
Fort Worth, Texas
Baylor College of Medicine - Advanced Liver Therapies
Houston, Texas
UT Health The University of Texas Health Science Center at Houston
Houston, Texas
American Research Corporation at Texas Liver Institute
San Antonio, Texas
Texas Digestive Disease Consultants
Southlake, Texas
Showing 40 of 181 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.